Maggie LeFlore

Managing Director, MedImmune Ventures, AstraZeneca

Maggie, who joined MedImmune Ventures as a managing director in 2007, transitioned into the role from her position as Head of R&D Ventures at AstraZeneca. As Head of R&D Ventures, she was on assignment to Advent International where she worked with the Healthcare and Life Sciences venture capital investment team. Previously, Maggie was the Global Alliance Director for Global Sciences and Information from 2001 to 2005, where she led an international group responsible for evaluation, negotiation and management of global technology platform collaborations. Prior to 2001, Maggie held business development and scientific management positions at Hybridon, Inc. (1997-2000); Oncogene Science Inc. (1994-1996); and Merrell Dow Pharmaceuticals (1985-1994). Originally trained as a biophysical chemist, with a B.S. in Chemistry from the University of Kansas, and a Ph.D. in Physical Chemistry from Indiana University, she trained in molecular and cellular biology as a post-doctoral fellow at the National Institutes of Health. Maggie is a board observer of Inotek, Inc, and Brain Cells, Inc.